drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Off-the-shelf, allogeneic CAR T-cell product using a 4SCAR design directed at CD138 (syndecan-1) to recognize malignant plasma cells and activate T-cell effector functions for myeloma cell killing.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Off-the-shelf allogeneic T cells engineered with a 4SCAR chimeric antigen receptor specific for CD138 (syndecan-1). CAR engagement activates CD3zeta and co-stimulatory signaling, inducing T-cell cytotoxicity and cytokine release to eliminate CD138-positive myeloma/plasma cells.
drug_name
Universal allogeneic anti-CD138 4SCAR T cells
nct_id_drug_ref
NCT06006741